A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

NCT04462822 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent
DRUG: ADVAIR DISKUS® 250/50

Sponsor

Respirent Pharmaceuticals Co Ltd.

Collaborators

[object Object]